UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 129

Sortiert nach

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

Cancer treatment reviews, 2020-06, Vol.86, p.102017-102017, Article 102017

2020

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

The New England journal of medicine, 2014-02, Vol.370 (8), p.709-722

2014

Link zum Volltext

Verfügbarkeit prüfen

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma

Journal of clinical oncology, 2015-07, Vol.33 (19), p.2166-2175

2015

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma

Neuro-oncology (Charlottesville, Va.), 2016-10, Vol.18 (10), p.1434-1441

2016

Link zum Volltext

Verfügbarkeit prüfen

Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy

Current neurology and neuroscience reports, 2013-05, Vol.13 (5), p.347-347, Article 347

2013

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy

Neuro-oncology (Charlottesville, Va.), 2016-07, Vol.18 (7), p.991-1001

2016

Link zum Volltext

Verfügbarkeit prüfen

Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio

Neuro-oncology (Charlottesville, Va.), 2018-03, Vol.20 (4), p.557-566

2018

Link zum Volltext

Verfügbarkeit prüfen

Cilengitide in glioblastoma: when did it fail?

The lancet oncology, 2014-09, Vol.15 (10), p.1044-1045

Chinot, Olivier L

2014

Link zum Volltext

Verfügbarkeit prüfen

Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population

Frontiers in oncology, 2018-10, Vol.8, p.426-426

2018

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

The lancet oncology, 2021-06, Vol.22 (6), p.813-823

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations

Cancer, 2004-05, Vol.100 (10), p.2208-2214

2004

Link zum Volltext

Verfügbarkeit prüfen

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

Journal of clinical oncology, 2015-09, Vol.33 (25), p.2735-2744

2015

Link zum Volltext

Verfügbarkeit prüfen

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Clinical cancer research, 2019-03, Vol.25 (6), p.1809-1816

2019

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

The lancet oncology, 2018-09, Vol.19 (9), p.1170-1179

2018

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial” [Eur J Cancer 198 (2024) 113475]

European journal of cancer (1990), 2024-06, Vol.204, p.114066-114066, Article 114066

2024

Link zum Volltext

Verfügbarkeit prüfen

Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial

European journal of cancer (1990), 2024-02, Vol.198, p.113475-113475, Article 113475

2024

Link zum Volltext

Verfügbarkeit prüfen

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma

European journal of cancer (1990), 2018-09, Vol.101, p.95-104

2018

Link zum Volltext

Verfügbarkeit prüfen

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio

Neuro-oncology (Charlottesville, Va.), 2016-09, Vol.18 (9), p.1313-1318

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Clinical cancer research, 2022-06, Vol.28 (11), p.2440-2448

2022

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date

Expert review of anticancer therapy, 2012-11, Vol.12 (11), p.1413-1427

Chinot, Olivier L

2012

Link zum Volltext

Verfügbarkeit prüfen

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial

Oncotarget, 2018-01, Vol.9 (6), p.6752-6762

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2015-07, Vol.17 (7), p.1007-1015

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 129

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(126)
Mit Volltextzugriff
(127)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(50)
Science & Technology
(50)
Humans
(44)
Oncology
(42)
Life Sciences
(30)
Male
(24)
Brain Neoplasms - Drug Therapy
(23)
Female
(22)
Aged
(21)
Glioblastoma - Drug Therapy
(21)
Middle Aged
(21)
Cancer
(18)
Glioblastoma
(18)
Adult
(16)
Neurosciences & Neurology
(16)
Clinical Neurology
(15)
Prognosis
(15)
Dacarbazine - Analogs & Derivatives
(14)
Bevacizumab
(13)
Angiogenesis Inhibitors - Therapeutic Use
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma

Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy

Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio

Cilengitide in glioblastoma: when did it fail?

Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O 6 -Methylguanine-DNA Methyltransferase Biomarker Analyses

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire

Corrigendum to “Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial” [Eur J Cancer 198 (2024) 113475]

Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio

Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

Suchergebnisse filtern